During exercise for patients on SGLT2 inhibitors, what is a key consideration?

During exercise for patients on SGLT2 inhibitors, what is a key consideration?

• A. Ensure hydration and watch for dehydration
• B. Avoid water during exercise
• C. Increase carbohydrate intake only after exercise
• D. Discontinue during exercise

Answer: (A)

Hydration is the key consideration. SGLT2 inhibitors cause more glucose to be excreted in the urine, which pulls water along and can lead to volume depletion. Exercise increases fluid loss through sweating, so the risk of dehydration, dizziness, or low blood pressure rises. Ensuring adequate fluids before, during, and after activity helps maintain blood volume and overall safety for people taking these meds. Watch for signs of dehydration such as thirst, dry mouth, dark urine, or lightheadedness, and consider electrolytes in longer or hot workouts. The other options aren’t appropriate: avoiding water during exercise increases dehydration risk; delaying carbohydrate intake isn’t the main safety concern here; and discontinuing the medication during exercise isn’t necessary and could raise glucose-related risks.

Hydration is the key consideration. SGLT2 inhibitors cause more glucose to be excreted in the urine, which pulls water along and can lead to volume depletion. Exercise increases fluid loss through sweating, so the risk of dehydration, dizziness, or low blood pressure rises. Ensuring adequate fluids before, during, and after activity helps maintain blood volume and overall safety for people taking these meds. Watch for signs of dehydration such as thirst, dry mouth, dark urine, or lightheadedness, and consider electrolytes in longer or hot workouts. The other options aren’t appropriate: avoiding water during exercise increases dehydration risk; delaying carbohydrate intake isn’t the main safety concern here; and discontinuing the medication during exercise isn’t necessary and could raise glucose-related risks.